GCP
CKPT

GSA Capital Partners’s Checkpoint Therapeutics CKPT Stock Holding History

GSA Capital Partners’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,986
Closed -$364K – 1515
2022
Q3 		$364K Buy
34,986
+28,646
+452% +$341K 0.05% 805
2022
Q2 		$65K Buy
+6,340
New +$83K 0.01% 1264

Other funds holding CKPT

TC
TwinBeech Capital Purchase, New York $553M AUM 0.21% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
PAS
Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GSA Capital Partners's CKPT Position: Q4 2022 in Review

GSA Capital Partners sold out of Checkpoint Therapeutics (CKPT) in Q4 2022, closing a stake of 34,986 shares — an estimated $364K sold.

GSA Capital Partners first reported a position in CKPT in Q2 2022 and held it in 2 quarters. The position peaked at $364K in Q3 2022. 39 funds tracked by Wall St. Rank hold CKPT as of Q4 2022.

  • GSA Capital Partners reported no remaining Checkpoint Therapeutics position as of Q4 2022 after selling out during the quarter.
  • GSA Capital Partners sold 34,986 Checkpoint Therapeutics shares in Q4 2022, an estimated $364K.
  • GSA Capital Partners first reported a position in Checkpoint Therapeutics in Q2 2022 and held it in 2 quarters.
  • GSA Capital Partners's Checkpoint Therapeutics position peaked at $364K in Q3 2022.
  • 39 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.